Samsung-nurtured Startup 

Responding to the market with speed & flexibility - paving the way for new opportunities

Wellysis is a startup spun off from Samsung SDS's Digital Healthcare Business Unit. 

Leveraging Samsung Electronics' bio-processors and Samsung SDS's experience in artificial intelligence (AI) and digital healthcare, Wellysis has experienced rapid growth while accelerating recruitment and investor relations. It was founded with the intention of responding to the market more independently, rapidly, and flexibly than before, paving the way for new opportunities.

According to industry sources, Wellysis started with a small number of employees at its inception but has achieved double-digit growth in recruitment this year. The company attributes its expansion to the high technical expertise and robust partnership network it cultivated while at Samsung.

Wellisys's founder, CEO Young Juhn, is a healthcare industry veteran with over 20 years of experience, including positions at companies like Johnson & Johnson in the United States. He joined Samsung SDS with the determination to elevate Korea's healthcare devices to the global top tier, despite Korea's leading positions in appliances and semiconductors. 

Alongside CEO Juhn, 3 other experts from Samsung SDS, including Chief Strategy Officer Kim Jong-woo, Chief Financial Officer Kim Jung-soo from Arthur Andersen and PWC Consulting, and Chief Technology Officer Rick Kim from HP, co-founded the company.

A flagship product of Wellisys is the S-Patch Ex solution, which monitors cardiac data and is primarily used by patients undergoing electrocardiogram tests in hospitals. Its main customer base consists of hospital-visiting patients with arrhythmias or potential risks of arrhythmia onset.

Especially noteworthy is the utilization of Samsung Electronics' dedicated bio-signal chip, the bio-processor, ensuring superior quality of the cardiac waveform collected by the device. Additionally, the solution has been validated in clinical trials conducted in 7 countries, incorporating digital transformation components such as devices, mobile, cloud, and AI to significantly enhance the efficiency of medical professionals' tasks.

In terms of patient convenience, the device, weighing a mere 9g, is designed to minimize discomfort during wear, and it reduces skin irritation issues among existing patients by minimizing the skin area where electrodes are attached.

Since the initial investment from Samsung Venture Investment Corporation (SVIC), Wellysis has attracted investments from pharmaceutical companies and others. In late May, it secured a 5 billion won investment from diagnostics reagent specialist Access Bio (950130). The company aims to enter the US market through securing references and validations in the domestic market.

A Wellisys representative stated, "We particularly focus on utilizing health examination cases in the domestic market, providing health examination services to Samsung employees through smooth collaboration with Kangbuk Samsung Hospital." They added, "The FDA certification process for entering the US market is currently underway."